Krystal Biotech, Inc. Common Stock vs. Vericel Corporation
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| KRYS | VCEL | |
|---|---|---|
| Market Cap | $11.00 billion | $2.07 billion |
| Revenue (TTM) | $440.48 million | — |
| Net Income (TTM) | $241.47 million | — |
KRYS leads on 1 of 1 size & scale factors.
Valuation
| KRYS | VCEL | |
|---|---|---|
| P/E Ratio | 44.55 | — |
| Price / Book | 8.09 | — |
| Price / Sales | 24.96 | — |
KRYS and VCEL split the valuation factors evenly.
Profitability
| KRYS | VCEL | |
|---|---|---|
| Net Margin | 54.82% | — |
| Return on Equity | 17.77% | — |
KRYS and VCEL split the profitability factors evenly.
Risk & Sentiment
| KRYS | VCEL | |
|---|---|---|
| Short Interest | 0.11% | 2.79% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, VCEL overview, VCEL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.